{"id":"https://openalex.org/W2280192011","doi":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","title":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial","display_name":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial","publication_year":2016,"publication_date":"2016-02-26","ids":{"openalex":"https://openalex.org/W2280192011","doi":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","mag":"2280192011","pmid":"https://pubmed.ncbi.nlm.nih.gov/27062408"},"language":"en","primary_location":{"id":"doi:10.1016/j.atherosclerosis.2016.02.029","doi":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","pdf_url":null,"source":{"id":"https://openalex.org/S206830620","display_name":"Atherosclerosis","issn_l":"0021-9150","issn":["0021-9150","1879-1484"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Atherosclerosis","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058350680","display_name":"Shun Ishibashi","orcid":"https://orcid.org/0000-0002-1063-1979","observed_orcids":["https://orcid.org/0000-0002-1063-1979"]},"institutions":[{"id":"https://openalex.org/I146500386","display_name":"Jichi Medical University","ror":"https://ror.org/010hz0g26","country_code":"JP","type":"education","lineage":["https://openalex.org/I146500386"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Shun Ishibashi","raw_affiliation_strings":["Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. Electronic address: ishibash@jichi.ac.jp","Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan"],"raw_orcid":"https://orcid.org/0000-0002-1063-1979","affiliations":[{"raw_affiliation_string":"Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. Electronic address: ishibash@jichi.ac.jp","institution_ids":["https://openalex.org/I146500386"]},{"raw_affiliation_string":"Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan","institution_ids":["https://openalex.org/I146500386"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089216722","display_name":"Shizuya Yamashita","orcid":"https://orcid.org/0000-0001-6645-4185","observed_orcids":["https://orcid.org/0000-0001-6645-4185"]},"institutions":[{"id":"https://openalex.org/I4405254471","display_name":"Rinku General Medical Center","ror":"https://ror.org/01v60bs72","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4405254471"]},{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Shizuya Yamashita","raw_affiliation_strings":["Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan; Rinku General Medical Center, 2-23 Ourai-kita, Rinku, Izumisano, Osaka 598-8577, Japan. Electronic address: shizu@imed2.med.osaka-u.ac.jp","Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan","Rinku General Medical Center, 2-23 Ourai-kita, Rinku, Izumisano, Osaka 598-8577, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan; Rinku General Medical Center, 2-23 Ourai-kita, Rinku, Izumisano, Osaka 598-8577, Japan. Electronic address: shizu@imed2.med.osaka-u.ac.jp","institution_ids":["https://openalex.org/I4405254471","https://openalex.org/I98285908"]},{"raw_affiliation_string":"Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan","institution_ids":["https://openalex.org/I98285908"]},{"raw_affiliation_string":"Rinku General Medical Center, 2-23 Ourai-kita, Rinku, Izumisano, Osaka 598-8577, Japan","institution_ids":["https://openalex.org/I4405254471"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076061467","display_name":"Hidenori Arai","orcid":"https://orcid.org/0000-0002-9000-6849","observed_orcids":["https://orcid.org/0000-0002-9000-6849","https://orcid.org/0000-0001-6747-8680"]},"institutions":[{"id":"https://openalex.org/I4210160102","display_name":"National Center for Geriatrics and Gerontology","ror":"https://ror.org/05h0rw812","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210160102"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Hidenori Arai","raw_affiliation_strings":["National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu, Aichi, 474-8511, Japan. Electronic address: harai@ncgg.go.jp","National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu, Aichi, 474-8511, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu, Aichi, 474-8511, Japan. Electronic address: harai@ncgg.go.jp","institution_ids":["https://openalex.org/I4210160102"]},{"raw_affiliation_string":"National Center for Geriatrics and Gerontology, 7-430 Morioka-cho, Obu, Aichi, 474-8511, Japan","institution_ids":["https://openalex.org/I4210160102"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067248419","display_name":"Eiichi Araki","orcid":"https://orcid.org/0000-0002-4064-7525","observed_orcids":["https://orcid.org/0000-0002-4064-7525"]},"institutions":[{"id":"https://openalex.org/I96036126","display_name":"Kumamoto University","ror":"https://ror.org/02cgss904","country_code":"JP","type":"education","lineage":["https://openalex.org/I96036126"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Eiichi Araki","raw_affiliation_strings":["Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan. Electronic address: earaki@gpo.kumamoto-u.ac.jp","Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan. Electronic address: earaki@gpo.kumamoto-u.ac.jp","institution_ids":["https://openalex.org/I96036126"]},{"raw_affiliation_string":"Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan","institution_ids":["https://openalex.org/I96036126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079640536","display_name":"Koutaro Yokote","orcid":"https://orcid.org/0000-0003-3033-4813","observed_orcids":["https://orcid.org/0000-0003-3033-4813"]},"institutions":[{"id":"https://openalex.org/I159385669","display_name":"Chiba University","ror":"https://ror.org/01hjzeq58","country_code":"JP","type":"education","lineage":["https://openalex.org/I159385669"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Koutaro Yokote","raw_affiliation_strings":["Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. Electronic address: kyokote@faculty.chiba-u.jp","Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. Electronic address: kyokote@faculty.chiba-u.jp","institution_ids":["https://openalex.org/I159385669"]},{"raw_affiliation_string":"Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan","institution_ids":["https://openalex.org/I159385669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012076071","display_name":"Hideki Suganami","orcid":"https://orcid.org/0000-0001-9130-0137","observed_orcids":["https://orcid.org/0000-0001-9130-0137"]},"institutions":[{"id":"https://openalex.org/I4210088742","display_name":"Kowa (Japan)","ror":"https://ror.org/009z2z347","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210088742"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Hideki Suganami","raw_affiliation_strings":["Clinical Data Science Department, Kowa Company, Ltd., 4-14, Nihonbashi-honcho 3 chome, Chuo-ku, Tokyo, 103-8433, Japan. Electronic address: suganami@kowa.co.jp","Clinical Data Science Department, Kowa Company, Ltd., 4-14, Nihonbashi-honcho 3 chome, Chuo-ku, Tokyo, 103-8433, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Data Science Department, Kowa Company, Ltd., 4-14, Nihonbashi-honcho 3 chome, Chuo-ku, Tokyo, 103-8433, Japan. Electronic address: suganami@kowa.co.jp","institution_ids":["https://openalex.org/I4210088742"]},{"raw_affiliation_string":"Clinical Data Science Department, Kowa Company, Ltd., 4-14, Nihonbashi-honcho 3 chome, Chuo-ku, Tokyo, 103-8433, Japan","institution_ids":["https://openalex.org/I4210088742"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111913611","display_name":"Jean\u2010Charles Fruchart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405271907","display_name":"Fondation Coeur et Art\u00e8res","ror":"https://ror.org/0387nka41","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4405271907"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Jean-Charles Fruchart","raw_affiliation_strings":["Fondation coeur et arteres, 96, rue Nationale, 59000, Lille, France. Electronic address: jean-charles.fruchart@fondacoeur.com","Fondation coeur et arteres, 96, rue Nationale, 59000, Lille, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fondation coeur et arteres, 96, rue Nationale, 59000, Lille, France. Electronic address: jean-charles.fruchart@fondacoeur.com","institution_ids":["https://openalex.org/I4405271907"]},{"raw_affiliation_string":"Fondation coeur et arteres, 96, rue Nationale, 59000, Lille, France","institution_ids":["https://openalex.org/I4405271907"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5107007603","display_name":"Tatsuhiko Kodama","orcid":"https://orcid.org/0000-0003-3747-7956","observed_orcids":["https://orcid.org/0000-0003-3747-7956"]},"institutions":[{"id":"https://openalex.org/I4405287038","display_name":"Research Center for Advanced Science and Technology, The University of Tokyo","ror":"https://ror.org/03xzehp18","country_code":"JP","type":"facility","lineage":["https://openalex.org/I4405287038","https://openalex.org/I74801974"]},{"id":"https://openalex.org/I74801974","display_name":"The University of Tokyo","ror":"https://ror.org/057zh3y96","country_code":"JP","type":"education","lineage":["https://openalex.org/I74801974"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Tatsuhiko Kodama","raw_affiliation_strings":["Laboratory for Systems Biology and Medicine (LSBM), Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8904, Japan. Electronic address: kodama@lsbm.org","Laboratory for Systems Biology and Medicine (LSBM), Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8904, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory for Systems Biology and Medicine (LSBM), Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8904, Japan. Electronic address: kodama@lsbm.org","institution_ids":["https://openalex.org/I4405287038","https://openalex.org/I74801974"]},{"raw_affiliation_string":"Laboratory for Systems Biology and Medicine (LSBM), Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, 153-8904, Japan","institution_ids":["https://openalex.org/I4405287038","https://openalex.org/I74801974"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5012076071","https://openalex.org/A5058350680","https://openalex.org/A5067248419","https://openalex.org/A5076061467","https://openalex.org/A5079640536","https://openalex.org/A5089216722","https://openalex.org/A5107007603","https://openalex.org/A5111913611"],"corresponding_institution_ids":["https://openalex.org/I146500386","https://openalex.org/I159385669","https://openalex.org/I4210088742","https://openalex.org/I4210160102","https://openalex.org/I4405254471","https://openalex.org/I4405271907","https://openalex.org/I4405287038","https://openalex.org/I74801974","https://openalex.org/I96036126","https://openalex.org/I98285908"],"apc_list":{"value":4020,"currency":"USD","value_usd":4020},"apc_paid":{"value":4020,"currency":"USD","value_usd":4020},"fwci":8.5781,"has_fulltext":false,"cited_by_count":214,"citation_normalized_percentile":{"value":0.98523418,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"249","issue":null,"first_page":"36","last_page":"43"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.8583999872207642,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11072","display_name":"Peroxisome Proliferator-Activated Receptors","score":0.8583999872207642,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.08649999648332596,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13430","display_name":"Lipid metabolism and disorders","score":0.045099999755620956,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pemafibrate","display_name":"pemafibrate","score":0.8460000157356262},{"id":"https://openalex.org/keywords/pparalpha-modulator","display_name":"PPAR\u03b1 modulator","score":0.8790000081062317},{"id":"https://openalex.org/keywords/dyslipidemia","display_name":"dyslipidemia","score":0.8259999752044678},{"id":"https://openalex.org/keywords/hypertriglyceridemia","display_name":"hypertriglyceridemia","score":0.9390000104904175},{"id":"https://openalex.org/keywords/low-hdl-cholesterol","display_name":"low HDL cholesterol","score":0.9330000281333923},{"id":"https://openalex.org/keywords/fenofibrate","display_name":"fenofibrate","score":0.8489999771118164},{"id":"https://openalex.org/keywords/triglyceride-lowering","display_name":"triglyceride lowering","score":0.8629999756813049},{"id":"https://openalex.org/keywords/hdl-cholesterol","display_name":"HDL cholesterol","score":0.7689999938011169},{"id":"https://openalex.org/keywords/remnant-cholesterol","display_name":"remnant cholesterol","score":0.8930000066757202},{"id":"https://openalex.org/keywords/apolipoprotein-b","display_name":"apolipoprotein B","score":0.9380000233650208},{"id":"https://openalex.org/keywords/apolipoprotein-c-iii","display_name":"apolipoprotein C-III","score":0.9800000190734863},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6940000057220459},{"id":"https://openalex.org/keywords/lipid-lowering-therapy","display_name":"lipid-lowering therapy","score":0.800000011920929}],"concepts":[{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.7935587763786316},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6030813455581665},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5224567651748657},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5135717391967773},{"id":"https://openalex.org/C202061045","wikidata":"https://www.wikidata.org/wiki/Q7200267","display_name":"Placebo-controlled study","level":5,"score":0.4374493956565857},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.42947447299957275},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.328670859336853},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.16483062505722046},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.05862748622894287},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001583","descriptor_name":"Benzoxazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002087","descriptor_name":"Butyrates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008075","descriptor_name":"Lipoproteins, HDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011345","descriptor_name":"Fenofibrate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014280","descriptor_name":"Triglycerides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047493","descriptor_name":"PPAR alpha","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D050171","descriptor_name":"Dyslipidemias","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D061214","descriptor_name":"Patient Safety","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.atherosclerosis.2016.02.029","doi":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","pdf_url":null,"source":{"id":"https://openalex.org/S206830620","display_name":"Atherosclerosis","issn_l":"0021-9150","issn":["0021-9150","1879-1484"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Atherosclerosis","raw_type":"journal-article"},{"id":"pmid:27062408","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27062408","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Atherosclerosis","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.1016/j.atherosclerosis.2016.02.029","doi":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.atherosclerosis.2016.02.029","pdf_url":null,"source":{"id":"https://openalex.org/S206830620","display_name":"Atherosclerosis","issn_l":"0021-9150","issn":["0021-9150","1879-1484"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Atherosclerosis","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320316238","display_name":"Kowa Company","ror":"https://ror.org/009z2z347"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W1615613652","https://openalex.org/W1972661406","https://openalex.org/W1983397453","https://openalex.org/W1994789322","https://openalex.org/W2017342841","https://openalex.org/W2019071303","https://openalex.org/W2030365295","https://openalex.org/W2054851194","https://openalex.org/W2056248487","https://openalex.org/W2071048602","https://openalex.org/W2089035720","https://openalex.org/W2092700213","https://openalex.org/W2096210401","https://openalex.org/W2108169164","https://openalex.org/W2114056762","https://openalex.org/W2114976556","https://openalex.org/W2119331212","https://openalex.org/W2143716053","https://openalex.org/W2144259092","https://openalex.org/W2164324917","https://openalex.org/W2185025112","https://openalex.org/W2198678228","https://openalex.org/W2200285648","https://openalex.org/W2589909250","https://openalex.org/W2601704071","https://openalex.org/W3145726055","https://openalex.org/W4236673002"],"related_works":["https://openalex.org/W2573584576","https://openalex.org/W2765263832","https://openalex.org/W2606681350","https://openalex.org/W2574726211","https://openalex.org/W2599479486","https://openalex.org/W2744310085","https://openalex.org/W2144259092","https://openalex.org/W2807918954","https://openalex.org/W2762341782","https://openalex.org/W2586612408"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1,48],"AIMS:":[2],"To":[3],"assess":[4],"the":[5,88,98,116,130,151,161,183],"efficacy":[6],"and":[7,26,31,40,145,172,194,208,215,227,236],"safety":[8],"of":[9,115,156],"K-877":[10,67,99,152,162,184,211,229],"(Pemafibrate),":[11],"a":[12,53,239],"novel":[13],"selective":[14],"peroxisome":[15],"proliferator-activated":[16],"receptor":[17],"\u03b1":[18],"modulator":[19],"(SPPARM\u03b1)":[20],"that":[21,114],"possesses":[22],"unique":[23],"PPAR\u03b1":[24],"activity":[25],"selectivity,":[27],"compared":[28,224],"with":[29,36,205],"placebo":[30,79,170,192,226],"fenofibrate":[32,74,117,173,195],"in":[33,150,160,169,182,191],"dyslipidaemic":[34,203,244],"patients":[35,65,204],"high":[37,206],"triglyceride":[38],"(TG)":[39],"low":[41,209],"high-density":[42],"lipoprotein":[43,134,139],"cholesterol":[44],"(HDL-C)":[45],"levels.":[46],"METHODS":[47],"RESULTS:":[49],"This":[50],"study":[51,62],"was":[52,165],"double":[54],"blind,":[55],"placebo-controlled,":[56],"parallel-group":[57],"12-week":[58],"clinical":[59],"trial.":[60],"The":[61,154],"randomized":[63],"224":[64],"to":[66,167,225,233,237],"0.025,":[68,100],"0.05,":[69,101],"0.1,":[70,102],"0.2":[71,103],"mg":[72,76,104,119,175,197],"BID,":[73],"100":[75,118,174,196],"QD,":[77],"or":[78,222],"(1:1:1:1:1:1)":[80],"groups.":[81,153,200],"Least":[82],"squares":[83],"mean":[84],"percent":[85],"changes":[86],"from":[87,129],"baseline":[89,131],"TG":[90,207],"levels":[91],"were":[92,111,147,187],"-30.9%,":[93],"-36.4%,":[94],"-42.6%,":[95],"-42.7%":[96],"for":[97,243],"BID":[105],"respectively":[106],"(p":[107],"<":[108,123],"0.001),":[109],"which":[110],"greater":[112],"than":[113,189],"QD":[120,176,198],"(-29.7%,":[121],"p":[122],"0.001)":[124],"group.":[125],"Statistically":[126],"significant":[127],"improvements":[128],"HDL-C,":[132,210,214],"very-low-density":[133],"cholesterol,":[135,137,140],"chylomicron":[136],"remnant":[138],"apolipoprotein":[141],"(apo)":[142],"B":[143],"(apoB),":[144],"apoC-III":[146],"also":[148],"observed":[149],"incidence":[155],"adverse":[157,178],"events":[158],"(AEs)":[159],"groups":[163,185],"(32.4-56.8%)":[164],"comparable":[166],"those":[168,190],"(47.2%)":[171],"(56.8%);":[177],"drug":[179],"reactions":[180],"(ADRs)":[181],"(2.7-5.4%)":[186],"less":[188],"(8.3%)":[193],"(10.8%)":[199],"CONCLUSION:":[201],"In":[202],"improved":[212],"TG,":[213],"other":[216],"lipid":[217],"parameters":[218],"without":[219],"increasing":[220],"AEs":[221],"ADRs,":[223],"fenofibrate.":[228],"can":[230],"be":[231,238],"expected":[232],"improve":[234],"atherogenicity":[235],"new":[240],"beneficial":[241],"treatment":[242],"patients.":[245]},"counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":24},{"year":2024,"cited_by_count":31},{"year":2023,"cited_by_count":15},{"year":2022,"cited_by_count":19},{"year":2021,"cited_by_count":25},{"year":2020,"cited_by_count":18},{"year":2019,"cited_by_count":18},{"year":2018,"cited_by_count":20},{"year":2017,"cited_by_count":23},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2016-06-24T00:00:00"}